{"schemaVersion":1,"research":true,"symbol":"zbh","name":"Zimmer Biomet Holdings","topic":"moat","path":"/stock/zbh/moat","status":"published","version":7,"updatedAt":"2026-10-19T16:17:44.764Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"uncertain","summary":"Zimmer Biomet has an established surgical support and consignment infrastructure, customer relationships and proprietary products. The supplied passages do not establish that these produce durable switching costs or technological superiority. Pricing power is weak: prices reduced first-half 2026 sales by 0.7%, including purchase incentives. Continuing demand and innovation provide offsets, but procurement pressure, margin compression and distribution disruption show erosion. Insufficient evidence of a durable moat does not establish interchangeable offerings or uniformly low barriers.","advantages":[{"mechanism":"switching_costs","claim":"Product-specific technical support, professional relationships and consigned inventory constitute an existing service infrastructure that could create switching friction; customer dependence and the cost of changing suppliers are not demonstrated.","durability":"The infrastructure is established, but its ability to protect demand or pricing over time remains unproven.","risks":"Purchasing-group members have no purchase obligation, most sales lack firm orders, and customer relationships partly depend on personnel and distributors. China distribution changes have generated actual claims.","invalidation":"The switching-cost hypothesis would be invalidated by documented customer migration despite continued technical support and inventory availability, or evidence that replacement suppliers require little retraining or operational adjustment.","competitors":[],"evidenceIds":["e1","e2","e3","e4"],"counterEvidenceIds":["e5","e6","e7","e8"]},{"mechanism":"intangible_assets","claim":"Proprietary technology and intellectual-property protections are current assets. Reported ROSA Shoulder clearance and first cases demonstrate development progress, but neither those achievements nor acquired robotics establish sustained competitive superiority.","durability":"No product-specific exclusivity duration, durable clinical advantage or sustained premium pricing is established. Monogram's anticipated contribution remains potential.","risks":"Technology can be circumvented or independently replicated, and commercial acceptance requires continued innovation. Realized price declines limit evidence of monetizable differentiation.","invalidation":"The differentiation hypothesis would be invalidated by equivalent competing technology eliminating product preference, loss of commercially important exclusivity, or persistent adoption weakness after cleared products become available.","competitors":[],"evidenceIds":["e9","e10","e11"],"counterEvidenceIds":["e12","e13","e14"]}],"evidence":[{"id":"e1","sourceId":"filing-1","location":"Business / Customers, Sales and Marketing / consignment sales","excerpt":"Consignment sales represented approximately 85 percent of our net sales in 2025."},{"id":"e2","sourceId":"filing-1","location":"Business / Customers, Sales and Marketing / product-specific sales training","excerpt":"We invest a significant amount of time and expense in training sales associates in how to use specific products and how to best inform surgeons of product uses and features."},{"id":"e3","sourceId":"filing-1","location":"Business / Customers, Sales and Marketing / surgeon technical support","excerpt":"Sales force representatives must have strong technical selling and medical education skills to provide technical support for surgeons."},{"id":"e4","sourceId":"filing-1","location":"Risk Factors / technical knowledge and professional customer relationships","excerpt":"Additionally, certain of our key employees and third parties have detailed knowledge of our products and instruments and have developed professional relationships with existing and potential customers due to this knowledge."},{"id":"e5","sourceId":"filing-1","location":"Business / Americas / preferred purchasing sources without purchase obligations","excerpt":"Generally, we are designated as one of several preferred purchasing sources for specified products, although members are not obligated to purchase our products."},{"id":"e6","sourceId":"filing-1","location":"Business / Distribution / absence of firm orders","excerpt":"Since most of our sales occur at the time of an elective procedure, we generally do not have firm orders."},{"id":"e7","sourceId":"filing-1","location":"Risk Factors / enforceability of employee and distributor restrictions","excerpt":"Recent legal and regulatory changes may affect our ability to enforce post-termination obligations from certain employees and third parties with respect to non-competition, non-solicitation and protection of confidential information, which may negatively impact our ability to retain key employees and third-party distributors and to protect our information and relationships with our customers."},{"id":"e8","sourceId":"filing-2","location":"Commitments and Contingencies / China distributor claims","excerpt":"In connection with our ongoing efforts to transform our sales and distribution strategies and go-to-market model in China, including making significant changes across our independent distributor network, some of the displaced or impacted distributors in China have formally and informally raised legal claims against us."},{"id":"e9","sourceId":"filing-1","location":"Risk Factors / intellectual-property protection arrangements","excerpt":"We rely on a combination of patent, copyright, trademark, trade secret and other intellectual property laws and nondisclosure, license, assignment and confidentiality arrangements to establish, maintain and protect our proprietary rights, as well as the intellectual property rights of third parties whose assets we license."},{"id":"e10","sourceId":"filing-8","location":"Recent Highlights / ROSA Shoulder clearance and first cases","excerpt":"•\nReceived U.S. FDA 510(k) clearance and completed first cases of the next generation ROSA® Shoulder System, the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques."},{"id":"e11","sourceId":"filing-2","location":"Business Combinations / expected Monogram robotics contribution","excerpt":"Monogram's semi- and fully-autonomous robotic technologies are expected to add to our suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively."},{"id":"e12","sourceId":"filing-1","location":"Risk Factors / patent challenges and circumvention","excerpt":"Further, our currently pending or future patent applications may not result in patents being issued to us, patents issued to or licensed by us in the past or in the future may be challenged or circumvented by competitors, and such patents may be found invalid, unenforceable or insufficiently broad to protect our technology or to provide us with any competitive advantage."},{"id":"e13","sourceId":"filing-1","location":"Risk Factors / independently developed equivalent information","excerpt":"We also cannot be certain that others will not independently develop substantially equivalent proprietary information."},{"id":"e14","sourceId":"filing-2","location":"MD&A / Pricing Trends / second-quarter and first-half 2026 price effects","excerpt":"Pricing Trends Global selling prices had a negative effect of 0.8 percent and 0.7 percent on year-over-year sales during the three and six-month periods ended June 30, 2026, respectively."},{"id":"e15","sourceId":"filing-2","location":"MD&A / Pricing Trends / volume-based purchase incentives","excerpt":"In addition, volume-based discounts to incentivize customer purchases had a negative effect on our pricing in both periods."},{"id":"e16","sourceId":"filing-4","location":"MD&A / 2024 Financial Highlights / positive price realization","excerpt":"Net sales growth was driven by a combination of market growth, new product introductions, positive price realization and commercial execution across the organization."},{"id":"e17","sourceId":"filing-6","location":"MD&A / Pricing Trends / reported partial inflation pass-through","excerpt":"However, we have had success in offsetting negative effects of pricing pressure due to internal initiatives and being able to pass some inflationary impacts on to customers."},{"id":"e18","sourceId":"filing-2","location":"MD&A / Volume and Mix / demand drivers and opportunistic purchases","excerpt":"In addition, opportunistic end-of-quarter customer purchases, increased ROSA® Robot and bone cement sales, market growth and new product introductions contributed positively to volume and mix trends in both periods."},{"id":"e19","sourceId":"filing-2","location":"Segment Information / sales, segment profit and pretax earnings","excerpt":"Segment operating profit measures by segment are as follows (in millions): 24 Americas EMEA Asia Pacific Total Three Months Ended June 30, Three Months Ended June 30, Three Months Ended June 30, Three Months Ended June 30, 2026 2025 2026 2025 2026 2025 2026 2025 Net Sales $ 1,359.0 $ 1,287.0 $ 478.5 $ 458.1 $ 339.5 $ 332.2 $ 2,177.0 $ 2,077.3 Cost of products sold, excluding intangible asset amortization 309.3 292.7 182.6 166.6 124.2 117.6 Selling, general and administrative 432.7 385.2 142.8 136.0 107.3 90.7 Research and development 71.1 73.6 1.9 1.7 3.9 3.5 Segment profit $ 546.0 $ 535.6 $ 151.1 $ 153.8 $ 104.1 $ 120.3 $ 801.2 $ 809.7 Corporate items 311.7 349.1 Intangible asset amortization 163.4 160.6 Other income (expense), net (1.9 ) (3.9 ) Interest expense, net 72.9 79.3 Earnings before income taxes $ 255.1 $ 224.6 Americas EMEA Asia Pacific Total Six Months Ended June 30, Six Months Ended June 30, Six Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 2026 2025 2026 2025 Net Sales $ 2,683.5 $ 2,493.8 $ 968.3 $ 899.9 $ 611.8 $ 592.7 $ 4,263.7 $ 3,986.4 Cost of products sold, excluding intangible asset amortization 618.0 570.9 369.0 332.5 212.1 201.0 Selling, general and administrative 858.2 744.8 292.3 259.3 195.3 175.9 Research and development 143.0 144.6 3.7 3.8 7.2 6.8 Segment profit $ 1,064.3 $ 1,033.5 $ 303.4 $ 304.3 $ 197.1 $ 209.1 $ 1,564.8 $ 1,546.9 Corporate items 540.1 643.1 Intangible asset amortization 325.5 311.6 Other income (expense), net 1.1 (6.9 ) Interest expense, net 141.7 145.5 Earnings before income taxes $ 556.4 $ 453.6 Depreciation and amortization included in segment profit is as follows (in millions): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Americas $ 45.1 $ 45.8 $ 90.0 $ 86.5 EMEA 16.8 15.9 33.8 31.5 Asia Pacific 15.7 15.0 31.1 30.2 Corporate items 29.8 34.5 60.4 66.4 Intangible asset amortization 163.4 160.6 325.5 311.6 Total $ 270.8 $ 271.8 $ 540.8 $ 526.2 16."},{"id":"e20","sourceId":"filing-4","location":"Risk Factors / realized China procurement effects","excerpt":"For example, China has implemented volume-based procurement (“VBP”) processes designed to reduce medical spending, which have in the past resulted in, and could in the future result in, reduced margins on covered devices and products, required renegotiation of distributor arrangements, and incurrence of inventory-related charges."},{"id":"e21","sourceId":"filing-1","location":"Business / Americas / purchasing-group volume discounts","excerpt":"In this region, we contract with group purchasing organizations and managed care accounts and have promoted unit growth by offering volume discounts to customer healthcare institutions within a specified group."},{"id":"e22","sourceId":"filing-1","location":"Business / Americas / purchasing-group contract duration","excerpt":"Contracts with group purchasing organizations generally have a term of three years, with extensions as warranted."},{"id":"e23","sourceId":"filing-2","location":"Condensed Consolidated Statements of Cash Flows / first-half 2026","excerpt":"AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions, unaudited) For the Six Months Ended June 30, 2026 2025 Cash flows provided by (used in) operating activities: Net earnings $ 437.9 $ 336.0 Adjustments to reconcile net earnings to cash provided by operating activities: Depreciation and amortization 540.8 526.2 Share-based compensation 48.8 40.8 Changes in operating assets and liabilities, net of acquired assets and liabilities Income taxes (80.1 ) (132.0 ) Receivables (24.0 ) (18.6 ) Inventories (51.4 ) (40.2 ) Accounts payable and accrued liabilities (91.0 ) 40.4 Other assets and liabilities 26.1 8.3 Net cash provided by operating activities 807.2 761.0 Cash flows provided by (used in) investing activities: Additions to instruments (162.6 ) (140.2 ) Additions to other property, plant and equipment (90.5 ) (94.7 ) Net investment hedge settlements 10.8 3.5 Business combination investments, net of acquired cash - (1,226.3 ) Acquisition of intangible assets (101.2 ) (32.4 ) Other investing activities (6.3 ) (0.3 ) Net cash used in investing activities (349.8 ) (1,490.4 ) Cash flows provided by (used in) financing activities: Net proceeds from revolving facilities 30.0 220.0 Proceeds from senior notes - 1,748.1 Redemption of senior notes - (863.0 ) Dividends paid to stockholders (93.4 ) (95.3 ) Proceeds from employee stock compensation plans 12.4 17.1 Business combination contingent consideration payments (69.2 ) (17.4 ) Debt issuance costs (1.3 ) (17.3 ) Repurchase of common stock (500.8 ) (237.0 ) Other financing activities (17.9 ) (16.1 ) Net cash (used in) provided by financing activities (640.3 ) 739.2 Effect of exchange rates on cash and cash equivalents 1.1 21.6 Change in cash and cash equivalents (181.9 ) 31.4 Cash and cash equivalents, beginning of year 591.9 525.5 Cash and cash equivalents, end of period $ 410.0 $ 556.9 The accompanying notes are an integral part of these condensed consolidated financial statements."},{"id":"e24","sourceId":"filing-2","location":"MD&A / Financing Activities / repurchases funded with cash and revolving borrowings","excerpt":"In the 2026 period, we repurchased $500.8 million of our common stock using cash on hand and net borrowings from our revolving credit facilities."},{"id":"e25","sourceId":"filing-2","location":"MD&A / restructuring charges incurred and expected","excerpt":"The 2025 Restructuring Plan is expected to result in total pre-tax charges of approximately $155 million by the end of 2027, of which approximately $147 million was incurred through June 30, 2026."},{"id":"e26","sourceId":"filing-2","location":"MD&A / expected restructuring savings","excerpt":"We expect to reduce gross annual pre-tax operating expenses by approximately $175 million relative to the 2024 baseline expenses by the end of 2027 as program benefits under the 2025 Restructuring Plan are realized."},{"id":"e27","sourceId":"filing-3","location":"Executive Compensation / 2025 target compensation mix","excerpt":"2025 Target Total Direct Compensation(1) NEO Base Salary Annual Incentive(2) PRSUs(2) (Grant Date Fair Value) RSUs(3) (Grant Date Fair Value) Ivan Tornos 8.2% 15.4% 38.2% 38.2% Suketu Upadhyay 15.0% 18.9% 33.1% 33.1% Kevin Thornal 6.5% 8.1% 42.7% 42.7% Jehanzeb Noor(4) 9.0% 9.6% 38.0% 28.8% Wilfred van Zuilen 21.4% 21.0% 28.8% 28.8% (1) Percentages are computed based on the underlying individual whole numbers and therefore may not equal 100%."},{"id":"e28","sourceId":"filing-3","location":"Executive Compensation / 2025 annual incentive financial weights","excerpt":"Zimmer Biomet 34 Executive compensation Element and Key Characteristics Objectives Base Salary • Only fixed compensation component; payable in cash • Reviewed annually and adjusted when appropriate • 2025 NEO increases: 3.35% - 4.5% • Provide a base level of competitive cash compensation • Recognize increased responsibilities through promotional increases • Attract and retain executive talent Annual Cash Incentive Opportunity • Variable compensation component payable in cash based on performance against established goals and assessment of individual performance • Target awards are based on percentage of base salary • Tied to company financial results and individual objectives to drive total company performance in 2025: o 40%: Constant currency revenue o 40%: Adjusted operating profit o 20%: Free cash flow • Payouts for 2025 could range between 0% and 200% of target • 2025 NEO payouts: 125.9% of target for Messrs."},{"id":"e29","sourceId":"filing-3","location":"Executive Compensation / executive stock ownership requirements","excerpt":"We require executives to hold equity with a value equal to a multiple of six times salary for our CEO and two or three times salary for each other NEO."},{"id":"e30","sourceId":"filing-3","location":"Executive Compensation / mandatory share retention","excerpt":"100% of net after-tax shares received upon vesting or exercise of awards must be retained until an executive meets the guideline."},{"id":"e31","sourceId":"filing-3","location":"Executive Compensation / incentive compensation clawbacks","excerpt":"Incentive compensation to executive officers under cash and equity incentive plans are subject to clawback in the event of financial restatements, in compliance with NYSE listing standards."},{"id":"e32","sourceId":"filing-4","location":"MD&A / 2024 ERP implementation / order fulfillment disruption","excerpt":"As a result of this ERP implementation, we experienced operational challenges which affected our ability to fulfill certain customer orders."},{"id":"e33","sourceId":"filing-4","location":"MD&A / 2024 ERP implementation / shipping recovery","excerpt":"Shipping levels returned to similar levels that existed prior to the implementation by the end of the year."},{"id":"e34","sourceId":"filing-2","location":"Business Combinations / achieved Monogram development milestone","excerpt":"The first development milestone was achieved in January 2026."},{"id":"e35","sourceId":"filing-3","location":"Proxy Summary / governance structures and existing compensation practices","excerpt":"Corporate Governance Strengths Board Composition Board Oversight and Stock Ownership ✓ Diverse Board with effective mix of skills, experiences and perspectives ✓ Robust Board and executive succession planning and risk oversight ✓ Active Board refreshment and average Board tenure of 9.2 years ✓ Rigorous stock ownership guidelines for directors and executives; new stock retention guidelines for named executive officers ✓ Effective annual Board and Board committee evaluation process ✓ Directors and executives prohibited from hedging and pledging our stock under our insider trading policy ✓ Majority voting and director resignation policy in uncontested director elections ✓ Independent director equity-based compensation not paid out until cessation of service Board Structure and Independence Shareholder Rights and Accountability ✓ 100% independent director nominees, except CEO ✓ Annual election of all directors ✓ Lead Independent Director role ✓ Proxy access right for shareholders ✓ 100% independent Board committees ✓ Single class voting structure (one share, one vote) ✓ Independent directors regularly meet without management present ✓ Charter permits shareholders to call a special meeting ✓ Robust Code of Business Conduct and Ethics applicable to directors, officers and employees ✓ Compensation Recovery (“Clawback”) Policy covers incentive-based compensation X No poison pill X No supermajority voting requirements Zimmer Biomet 3 Proxy Statement SUMMARY Proposal 2 – Ratification of the Appointment of PwC Our Board recommends a vote FOR this proposal ● PwC’s report contained in our 2025 Annual Report is unqualified ● Audit and audit-related fees represent 85% of total fees paid to PwC for 2025 Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation Our Board recommends a vote FOR this proposal Executive Compensation Best Practices What We Do ✓ Pay for performance ✓ Require robust stock ownership guidelines ✓ Require termination of employment in connection with a change in control for accelerated equity vesting (double trigger) ✓ Require non-competition agreement for equity award eligibility ✓ Require shares received upon equity award vesting to be retained in accordance with stock ownership guidelines ✓ Subject executives’ cash and equity-based incentives to clawback, including in the event of: ● an accounting restatement due to material noncompliance with financial reporting requirements under the securities laws (as to cash bonuses and equity-based incentives that are performance-based) ● certain violations of our Code of Business Conduct and Ethics or other conduct deemed detrimental to the interests of the company (as to equity-based incentives) What We Don’t Do x Offer employment contracts to our executives, except as required in non-U.S."},{"id":"e36","sourceId":"filing-3","location":"Proxy Summary / combined chairman and CEO roles and independent-chair proposal","excerpt":"jurisdictions x Pay dividends or accrue dividend equivalents on unearned performance-based equity awards x Provide excise tax gross-ups in new change in control severance agreements (since 2009) x Allow hedging or pledging of company securities x Reprice or exchange underwater stock options without shareholder approval Proposal 4 – Shareholder Proposal for Independent Board Chairman Our Board recommends a vote AGAINST this proposal ● It is important for the Board to have the flexibility to determine the most effective leadership structure using its best business judgment in light of the company’s circumstances at any given time ● A one-size-fits-all leadership structure is not in the best interests of the company or its shareholders ● A Lead Independent Director will be maintained whenever the Chairman is not an independent director ● The roles, responsibilities, and authorities of the company’s Lead Independent Director are equivalent to that of an independent Chairman, providing for an effective counterweight when the Chairman is not an independent director ● Our independent Board, which consists entirely of independent directors other than our Chairman and CEO, combined with the robust independent Lead Independent Director role and our strong corporate governance practices and policies, enable effective Board oversight Zimmer Biomet 4 Proxy Statement SUMMARY CORPORATE GOVERNANCE Every day, the Zimmer Biomet team works towards our mission of alleviating pain and improving quality of life for people around the world."},{"id":"e37","sourceId":"filing-4","location":"Controls and Procedures / unqualified 2024 internal-control audit opinion","excerpt":"PricewaterhouseCoopers LLP, an independent registered public accounting firm, audited the effectiveness of our internal control over financial reporting as of December 31, 2024 and issued an unqualified opinion thereon as stated in their report, which appears under Item 8 of this Annual Report on Form 10-K."},{"id":"e38","sourceId":"filing-1","location":"Controls and Procedures / Paragon 28 exclusion from 2025 assessment","excerpt":"Management excluded Paragon 28 from its evaluation of internal control over financial reporting as of December 31, 2025."},{"id":"e39","sourceId":"filing-8","location":"Gross Margin Reconciliation / quarterly and first-half reported and adjusted margins","excerpt":"19.3\n \n \n \n 23.2\n \n \n Intangible asset amortization\n \n 163.4\n \n \n \n 160.6\n \n \n \n \n 325.5\n \n \n \n 311.6\n \n \n Adjusted gross profit\n $\n 1,547.5\n \n \n $\n 1,502.1\n \n \n \n $\n 3,071.4\n \n \n $\n 2,867.6\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Gross margin\n \n 63.3\n \n %\n \n 63.8\n \n %\n \n \n 63.9\n \n %\n \n 63.5\n \n %\n Inventory and manufacturing-related charges\n \n 0.3\n \n \n \n 0.8\n \n \n \n \n 0.5\n \n \n \n 0.6\n \n \n Intangible asset amortization\n \n 7.5\n \n \n \n 7.7\n \n \n \n \n 7.6\n \n \n \n 7.8\n \n \n Adjusted gross margin\n \n 71.1\n \n %\n \n 72.3\n \n %\n \n \n 72.0\n \n %\n \n 71.9\n \n %\n \n Page 20 of 23\n \n \n \n ZIMMER BIOMET HOLDINGS, INC."},{"id":"e40","sourceId":"filing-8","location":"Operating Profit Reconciliation / reported and adjusted operating results","excerpt":"FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 and 2025\n (in millions, unaudited)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Three Months Ended June 30,\n \n \n \n Six Months Ended June 30,\n \n \n \n 2026\n \n \n 2025\n \n \n \n 2026\n \n \n 2025\n \n \n Operating profit\n $\n 326.1\n \n \n $\n 300.0\n \n \n \n $\n 699.2\n \n \n $\n 592.3\n \n \n Inventory and manufacturing-related charges\n \n 6.0\n \n \n \n 17.0\n \n \n \n \n 19.3\n \n \n \n 23.2\n \n \n Intangible asset amortization\n \n 163.4\n \n \n \n 160.6\n \n \n \n \n 325.5\n \n \n \n 311.6\n \n \n Restructuring and other cost reduction initiatives\n \n 29.8\n \n \n \n 17.5\n \n \n \n \n 36.1\n \n \n \n 53.5\n \n \n Acquisition, integration, divestiture and related\n \n 18.1\n \n \n \n 78.9\n \n \n \n \n 33.7\n \n \n \n 89.5\n \n \n Litigation\n \n 12.3\n \n \n \n -\n \n \n \n \n 12.3\n \n \n \n -\n \n \n European Union Medical Device Regulation\n \n -\n \n \n \n 4.3\n \n \n \n \n -\n \n \n \n 8.7\n \n \n Other charges\n \n 4.0\n \n \n \n 0.3\n \n \n \n \n 4.1\n \n \n \n 0.2\n \n \n Adjusted operating profit\n $\n 559.7\n \n \n $\n 578.5\n \n \n \n $\n 1,130.2\n \n \n $\n 1,079.0\nAdjusted effective tax rate\n \n 18.0\n \n %\n \n 18.2\n \n %\n \n \n 18.0\n \n %\n \n 18.2\n \n %\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n (1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges"},{"id":"e41","sourceId":"filing-2","location":"Business Combinations / conditional Monogram consideration through 2030","excerpt":"The CVRs issued to Monogram common stockholders may result in up to approximately $570 million in additional consideration if certain product development, regulatory and revenue milestones are achieved through 2030."}],"changes":["The uncertain verdict and all eight previously assessed pricing and management grades remain supported after re-examination against this catalog; four moat criteria are explicitly null.","Added the reported ROSA Shoulder clearance and first cases as development evidence, without treating the issuer's industry-first claim as proof of durable superiority.","Expanded margin assessment to include reported and adjusted gross and operating results, which reinforce a mixed conclusion.","Removed reliance on prior analysis as evidence; every cited assessment now maps to supplied excerpt IDs."],"limitations":["The competition passages disclose generic competitors without identifying product-market rivals by name. Companies mentioned in executive biographies are not established as competitors by those references; competitor arrays therefore remain empty.","Sources are predominantly issuer filings and issuer releases. Operating results and contractual disclosures support numerical assessments, while leadership statements and expected benefits do not establish exceptional performance.","Customer retention rates, measured switching costs, comparative clinical outcomes, market-share persistence and product-specific exclusivity durations are absent.","The proxy supplies actual compensation structures and ownership requirements, but the selected passages do not establish executives' ownership compliance or complete long-term award outcomes.","Complete price-reset, termination and exclusivity provisions are unavailable. Contractual freedom is assessed from disclosed purchasing arrangements and realized procurement effects.","Dates supplied for all sources have dateKind filed; they are treated as filing dates. Later retrieval or the current assessment date does not extend the operating evidence beyond the supplied periods.","No excerpt text is reproduced; evidence references identify immutable catalog passages."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":null,"rationale":"Technical support, consignment infrastructure and proprietary rights are established, but their superiority and resulting barriers are unproven. The moat remains uncertain.","evidenceIds":["e1","e2","e3","e9","e10"]},{"criterion":"durability","grade":null,"rationale":"The catalog does not establish enduring customer lock-in or commercially decisive exclusivity. Patent protections and acquired robotics alone cannot establish duration.","evidenceIds":["e5","e11","e12","e13"]},{"criterion":"customer_dependency","grade":null,"rationale":"Professional relationships support a dependency hypothesis, but there is no demonstrated cost of switching, and preferred-source customers have no purchase obligation.","evidenceIds":["e3","e4","e5","e6"]},{"criterion":"erosion_resilience","grade":null,"rationale":"Demand and product development persist alongside realized pricing pressure and distribution disputes. Without an established structural advantage, resilience of a moat cannot be determined.","evidenceIds":["e8","e10","e14","e18","e20"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":1,"rationale":"Prices reduced second-quarter and first-half 2026 sales by 0.8% and 0.7%, including volume incentives. Positive 2024 realization and management's reported partial inflation pass-through provide offsets, but current pricing is fragile.","evidenceIds":["e14","e15","e16","e17"]},{"criterion":"retention","grade":2,"rationale":"Indirect operating evidence from ongoing product demand, technical support and established relationships supports repeat business. Opportunistic purchases and nonbinding preferred-source arrangements weaken the inference; no retention rate is asserted.","evidenceIds":["e1","e3","e4","e5","e18"]},{"criterion":"margin_resilience","grade":2,"rationale":"First-half reported gross margin improved from 63.5% to 63.9%, but second-quarter gross margin fell from 63.8% to 63.3%. Reported operating profit improved while second-quarter adjusted operating profit and segment profit declined despite higher sales. Historical procurement-related margin reductions reinforce a mixed assessment.","evidenceIds":["e19","e20","e39","e40"]},{"criterion":"contractual_freedom","grade":1,"rationale":"Three-year purchasing-group contracts provide access alongside other preferred sources without purchase obligations. Volume discounts and realized procurement-driven distributor renegotiation demonstrate constrained terms. Complete price-reset provisions are absent.","evidenceIds":["e5","e20","e21","e22"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"First-half operating cash flow of $807.2 million supported instrument and plant investment, but $500.8 million of repurchases used cash and revolving borrowings as cash declined. Acquisition commitments and restructuring charges are documented; acquisition returns and projected savings remain unproven.","evidenceIds":["e23","e24","e25","e26","e41"]},{"criterion":"incentive_alignment","grade":3,"rationale":"Disclosed 2025 compensation emphasizes equity, with annual incentives tied to revenue, adjusted operating profit and free cash flow. Salary-based ownership requirements, mandatory share retention and clawbacks provide strong actual alignment mechanisms. Ownership compliance and exceptional long-term pay-performance alignment are not established.","evidenceIds":["e27","e28","e29","e30","e31"]},{"criterion":"execution","grade":2,"rationale":"Indirect operating evidence is mixed: demand and cash generation continued, shipping recovered after ERP disruption, Monogram achieved a development milestone, and ROSA Shoulder reached clearance and first cases. Order-fulfillment disruption and China distributor claims offset these achievements. Acquisition and purchase-timing effects limit conclusions from growth.","evidenceIds":["e8","e10","e18","e23","e32","e33","e34"]},{"criterion":"governance","grade":3,"rationale":"Annual elections, independent committees, shareholder rights, a lead independent director and clawbacks support strong formal governance. The unqualified 2024 internal-control audit adds demonstrated oversight evidence. Combined chairman and CEO roles and the Paragon 28 exclusion limit confidence. The independent-chair proposal is not treated as adopted.","evidenceIds":["e31","e35","e36","e37","e38"]}]}],"financialAssessments":[],"qualityPolicy":"quality-scores-2","sourcePolicy":"issuer-evidence-7","basisHash":"b8cddedcb74dba341464360525d3623202698c567d65d17230e194008f30cbfb","updatedAt":"2026-10-19T16:17:44.764Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526059853/zbh-20251231.htm","publishedAt":"2026-02-20","sha256":"a6382937c46b796d1bcc7c63f65fb23e3c541758328840a59af057ed7e4472a6","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526335044/zbh-20260630.htm","publishedAt":"2026-08-05","sha256":"aee805d30adb7b1c538f433b036159cf1a0dc5650a74428bd5ee332d09464772","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526135661/zbh-20260331.htm","publishedAt":"2026-04-01","sha256":"76d80d488fa9599c85ab6fd025eed8a460d524d9b3f7bcb37953739f3054581d","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025026604/zbh-20241231.htm","publishedAt":"2025-02-25","sha256":"b85fe5ab21a89639521ada629d9854e375ef25d98f8a18e8deac8f98bb06b5c7","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024019353/zbh-20231231.htm","publishedAt":"2024-02-23","sha256":"b9a3de8055efc2bd65ec5343978bdc8901d7329c67a8d133a7993dc9da25f8ac","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526201710/zbh-20260331.htm","publishedAt":"2026-05-01","sha256":"382925f17970f34ae9e91491056f7ffcfa30acc0eac36ddc7282f53d074fa83c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526385256/d304716dex991.htm","publishedAt":"2026-09-08","sha256":"a59c1179472205b922eb60f03a2374af9c86f0cecf4f47f3db117a3b10749f69","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526333761/zbh-ex99_1.htm","publishedAt":"2026-08-05","sha256":"6e00bbdcff5fafb8ba5f9a84476aff5935ab14970f3e0bb4fbc8e8a059f50b30","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526218098/zbh-ex99_1.htm","publishedAt":"2026-05-12","sha256":"d1417d75bdd4b5d0827a25ea566999e247734fc489b737a95dbf45a591dc6b54","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:efacfd83c7c8967cf957979e8f12b58664bc04afe10bec28a564d11a823854c9","usage":{"input_tokens":114380,"cached_input_tokens":21120,"cache_write_input_tokens":0,"output_tokens":3492,"reasoning_output_tokens":68}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":70.12582629335647,"operating_margin":9.955080268497486,"roic":3.866422118920375,"fcf_margin":16.936780582425158,"sbc_revenue":1.0885378116944437},"issues":{"peg":"Prior-year TTM earnings per diluted share is zero or negative; a growth-adjusted multiple is undefined.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","buybacks":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":70.90015706278189,"operating_margin":10.033285782215883,"roic":2.7456156613486438,"fcf_margin":16.834536520699146,"sbc_revenue":1.5129901007219126},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":71.81845230045171,"operating_margin":17.27975981174434,"roic":6.974997097945529,"fcf_margin":17.452868464472154,"sbc_revenue":1.3497065267371724},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":71.46354804261193,"operating_margin":16.743937696976012,"roic":6.238135009442691,"fcf_margin":16.872867449795535,"sbc_revenue":1.3153439429062588},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":69.70539998785155,"operating_margin":13.340217457328555,"roic":4.9325189165404275,"fcf_margin":17.88981352122942,"sbc_revenue":1.0957905606511573},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%.","interest_coverage":"The reported inputs required for this metric are unavailable in the extracted statements for this period."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526059853/zbh-20251231.htm","publishedAt":"2026-02-20","sha256":"a6382937c46b796d1bcc7c63f65fb23e3c541758328840a59af057ed7e4472a6","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526335044/zbh-20260630.htm","publishedAt":"2026-08-05","sha256":"aee805d30adb7b1c538f433b036159cf1a0dc5650a74428bd5ee332d09464772","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526135661/zbh-20260331.htm","publishedAt":"2026-04-01","sha256":"76d80d488fa9599c85ab6fd025eed8a460d524d9b3f7bcb37953739f3054581d","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025026604/zbh-20241231.htm","publishedAt":"2025-02-25","sha256":"b85fe5ab21a89639521ada629d9854e375ef25d98f8a18e8deac8f98bb06b5c7","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024019353/zbh-20231231.htm","publishedAt":"2024-02-23","sha256":"b9a3de8055efc2bd65ec5343978bdc8901d7329c67a8d133a7993dc9da25f8ac","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526201710/zbh-20260331.htm","publishedAt":"2026-05-01","sha256":"382925f17970f34ae9e91491056f7ffcfa30acc0eac36ddc7282f53d074fa83c","dateKind":"filed","citationPolicy":"numeric-lines-1"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526385256/d304716dex991.htm","publishedAt":"2026-09-08","sha256":"a59c1179472205b922eb60f03a2374af9c86f0cecf4f47f3db117a3b10749f69","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526333761/zbh-ex99_1.htm","publishedAt":"2026-08-05","sha256":"6e00bbdcff5fafb8ba5f9a84476aff5935ab14970f3e0bb4fbc8e8a059f50b30","citationPolicy":"numeric-lines-1","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/1136869/000119312526218098/zbh-ex99_1.htm","publishedAt":"2026-05-12","sha256":"d1417d75bdd4b5d0827a25ea566999e247734fc489b737a95dbf45a591dc6b54","citationPolicy":"numeric-lines-1","dateKind":"filed"}],"history":[{"version":7,"updatedAt":"2026-10-22T23:06:10.367Z","verdict":"uncertain","value":null},{"version":6,"updatedAt":"2026-10-19T18:33:29.802Z","verdict":"uncertain","value":null},{"version":5,"updatedAt":"2026-10-19T13:57:15.039Z","verdict":"uncertain","value":null},{"version":4,"updatedAt":"2026-10-18T16:49:32.080Z","verdict":"uncertain","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"uncertain","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"uncertain","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}